Six Interferon-Stimulated Genes as Biomarkers of M1 Macrophage Polarization in Psoriasis

六种干扰素刺激基因作为银屑病中M1巨噬细胞极化的生物标志物

阅读:2

Abstract

BACKGROUND: Psoriasis is a chronic, immune-mediated, inflammatory skin disease characterized by abnormal keratinocyte proliferation, in which M1 macrophage polarization plays a critical role. However, the specific biomarkers and mechanisms underlying macrophage polarization in psoriasis remain unclear. METHODS: We analyzed the psoriasis dataset (GSE14905) to identify differentially expressed genes and applied weighted gene co-expression network analysis to identify key module genes. Macrophage polarization-related (MPR) genes were extracted from the Rummagene database, and MPR genes in psoriasis were identified through Venn analysis. Functional enrichment analysis (GO/KEGG) revealed associated pathways, while six CytoHubba algorithms determined hub genes, with diagnostic potential assessed via ROC curves. Single-gene GSEA further explored biological functions, and single-cell sequencing analysis was performed. Finally, the expression of hub genes and M1 macrophage markers (CD80/CD86) was experimentally validated in psoriasis mouse models. RESULTS: Six hub genes (ISG15, RSAD2, IFIT3, OASL, GBP1, and IFIT1) were identified through cytoHubba algorithms. Functional enrichment analysis revealed significant associations between psoriasis-associated macrophage polarization and the RIG-I-like receptor, NOD-like receptor, and cAMP signaling pathways. Experimental validation verified the increased expression of these hub genes and M1 macrophage markers in LPS-stimulated RAW264.7 murine macrophages and IMQ-induced psoriasis animal models. CONCLUSION: Our findings suggest that six interferon-responsive genes (ISG15, RSAD2, IFIT3, OASL, GBP1, and IFIT1) could serve as potential biomarkers for M1 macrophage polarization in psoriasis. Targeting macrophage polarization through IFN pathway inhibition may offer novel therapeutic strategies, particularly for patients with prominent IFN signatures refractory to conventional treatments.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。